Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat

Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat

Source: 
BioSpace
snippet: 

New Jersey-based Hepion Pharmaceuticals claimed a Phase II win in the potentially lucrative non-alcoholic steatohepatitis space Monday, releasing positive top-line data from its Phase II trial of oral drug candidate rencofilstat.